Histone deacetylase inhibitors globally enhance H3/H4 tail acetylation without affecting H3 lysine 56 acetylation

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Drogaris, Paul ^a,b   Villeneuve, Valérie ^a,b   Pomiès, Christelle ^a   Lee, Eun Hye ^a   Bourdeau, Véronique ^b   Bonneil, Éric ^a   Ferbeyre, Gerardo ^b   Verreault, Alain ^a,b   Thibault, Pierre ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942102316     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00220     Document Type: Article

References (54)

1. Davey, C. A., Sargent, D. F., Luger, K, Maeder, A. W. & Richmond, T. J. Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 A resolution. J Mol Biol 319, 1097-1113 (2002).
2. Luger, K. Dynamic nucleosomes. Chromosome Res 14, 5-16 (2006).
3. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
4. Masumoto, H., Hawke, D., Kobayashi, R. & Verreault, A. A role for cell-cycleregulated histone H3 lysine 56 acétylation in the DNA damage response. Nature 436, 294-298 (2005).
5. Van Leeuwen, F., Gafken, P. R. & Gottschling, D. E. Dotlp modulates silencing in yeast by méthylation of the nucleosome core. Cell 109, 745-756 (2002).
6. Ye, J. et al. Histone H4 lysine 91 acétylation: a core domain modification associated with chromatin assembly. Mol Cell 18, 123-130 (2005).
7. Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41-45 (2000).
8. Morales, V. et al. Chromatin structure and dynamics: functional implications. Biochimie 83, 1029-1039 (2001).
9. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769-784 (2006).
10. Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265, 17174-17179 (1990).
11. Halkidou, K. et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177-189 (2004).
12. Minucci, S., Nervi, C., Lo Coco, F. & Pelicci, P. G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110-3115 (2001).
13. Fraga, M. F. et al. Loss of acetylation at Lysl6 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37, 391-400 (2005).
14. Lee, M. J., Kim, Y. S., Kummar, S., Giaccone, G. & Trepel, J. B. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20, 639-649 (2008).
15. Prince, H. M., Bishton, M. J. & Harrison, S. J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15, 3958-3969 (2009).
16. Stimson, L., Wood, V., Khan, O., Fotheringham, S. & La Thangue, N. B. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20, 1293-1302.
17. Bots, M. & Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin Cancer Res 15, 3970-3977 (2009).
18. Dokmanovic, M., Clarke, C. & Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5, 981-989 (2007).
19. Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R. & Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247-1252 (2007).
20. Campas-Moya, C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Bare) 45, 787-795 (2009).
21. Beckers, T. et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121, 1138-1148 (2007).
22. Stimson, L. & La Thangue, N. B. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280, 177-183 (2009).
23. Durbin, K. R. et al. Intact mass detection, interpretation, and visualization to automate Top-Down proteomics on a large scale. Proteomics 10, 3589-3597 (2010).
24. Siuti, N. & Kelleher, N. L. Efficient readout of posttranslational codes on the 50-residue tail of histone H3 by high-resolution MS/MS. Anal Biochem 396, 180-187 (2010).
25. Drogaris, P., Wurtele, H., Masumoto, H., Verreault, A. & Thibault, P. Comprehensive profiling of histone modifications using a label-free approach and its applications in determining structure-function relationships. Anal Chem 80, 6698-6707 (2008).
26. Ninios, Y. P., Sekeri-Pataryas, K. E. & Sourlingas, T. G. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor trichostatin A. Leukemia Res 34, 786-792 (2010).
27. Johnstone, R. W. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discovery 1, 287-299 (2002).
28. Benson, L. J. et al. Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange. JBiol Chem 281, 9287-9296 (2006).
29. Loyola, A., Bonaldi, T., Roche, D., Imhof, A. & Almouzni, G. PTMs on H3 variants before chromatin assembly potentiate their final epigenetic state. Mol Cell 24, 309-316 (2006).
30. Sobel, R. E., Cook, R. G., Perry, C. A., Annunziato, A. T. & Allis, C. D. Conservation of deposition-related acetylation sites in newly synthesized histones H3 and H4. Proc Natl Acad Sci USA 92, 1237-1241 (1995).
31. Verreault, A., Kaufman, P. D., Kobayashi, R. & Stillman, B. Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell 87, 95-104 (1996).
32. Anoopkumar-Dukie, S. et al. Resazurin assay of radiation response in cultured cells. Br J Radiol 78, 945-947 (2005).
33. Song, O. K, Wang, X., Waterborg, J. H. & Sternglanz, R. An N-α-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A. J Biol Chem 278, 38109-38112 (2003).
34. Marzluff, W. F., Gongidi, P., Woods, K. R., Jin, J. & Maltais, L. J. The human and mouse replication-dependent histone genes. Genomics 80, 487-498 (2002).
35. Orsi, G. A., Couble, P. & Loppin, B. Epigenetic and replacement roles of histone variant H3.3 in reproduction and development. Int J Dev Biol 53, 231-243 (2009).
36. Falick, A. M. et al. ABRF-PRG07: advanced quantitative proteomics study. J Biomol Tech 22, 21-26 (2011).
37. Swaney, D. L., McAlister, G. C. & Coon, J. J. Decision tree-driven tandem mass spectrometry for shotgun proteomics. Nat Methods 5, 959-964 (2008).
38. Battu, A., Ray, A. & Wani, A. A. ASF1A and ATM regulate H3K56-mediated cellcycle checkpoint recovery in response to UV irradiation. Nucleic Acids Res 39, 7931-7945 (2011).
39. Das, C., Lucia, M. S., Hansen, K. C. & Tyler, J. K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459, 113-117 (2009).
40. Kong, S. et al. The type III histone deacetylase Sirtl protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclafl promoter to inhibit T cell activation. J Biol Chem 286, 16967-16975 (2011).
41. Li, Y. et al. And-1 is required for the stability of histone acetyltransferase Gcn5. Oncogene [Epub ahead of print] PMID: 21987584 (2011).
42. Lo, K. A. et al. Genome-wide profiling of H3K56 acetylation and transcription factor binding sites in human adipocytes. PLoS One 6, el9778 (2011).
43. Michishita, E. et al. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle 8, 2664-2666 (2009).
44. Miller, K. M. et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17, 1144-1151 (2010).
45. Schwer, B. et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci USA 107, 21790-21794 (2010).
46. Tjeertes, J. V., Miller, K. M. & Jackson, S. P. Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 28, 1878-1889 (2009).
47. Vempati, R. K. & Haidar, D. DNA damage in the presence of chemical genotoxic agents induce acetylation of H3K56 and H4K16 but not H3K9 in mammalian cells. Mol Biol Rep 39, 303-308 (2012).
48. Vempati, R. K. et al. p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals. J Biol Chem 285, 28553-28564 (2010).
49. Xie, W. et al. Histone H3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol Cell 33, 417-427 (2009).
50. Yuan, J., Pu, M., Zhang, Z. & Lou, Z. Histone H3-K56 acetylation is important for genomic stability in mammals. Cell Cycle 8, 1747-1753 (2009).
51. Celic, I. et al. The sirtuins Hst3 and Hst4p preserve genome integrity by controlling histone H3 lysine 56 deacetylation. Curr Biol 16, 1280-1289 (2006).
52. Waterborg, J. H. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol 80, 363-378 (2002).
53. Battu, A., Ray, A. & Wani, A. A. ASF1A and ATM regulate H3K56-mediated cellcycle checkpoint recovery in response to UV irradiation. Nucleic Acids Res 39, 7931-7945 (2011).
54. Dyer, P. N. et al. Reconstitution of nucleosome core particles from recombinant histones and DNA. Methods Enzymol 375, 23-44 (2004).